NCT00674557View on ClinicalTrials.gov

Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

June 30, 2008

Study Completion Date

March 31, 2009

Conditions
Breast Cancer
Interventions
DRUG

SOD1 inhibitor ATN-224

DRUG

exemestane

GENETIC

protein expression analysis

GENETIC

proteomic profiling

OTHER

laboratory biomarker analysis

OTHER

pharmacological study

Trial Locations (1)

OX3 7LJ

Cancer Research UK Medical Oncology Unit at Churchill Hospital & Weatherall Institute of Molecular Medicine - Oxford, Oxford

Sponsors

Lead Sponsor

Cancer Research UK
All Listed Sponsors
lead

Cancer Research UK

OTHER